Hi Börsen,
Although a bit old, the video and our Initiation of Coverage report are mostly still relevant. The main developments since recording the vid have been the faster than expected development of the phase I/II BEXMAB trial investigating bexmarilimab for treatment of blood cancers. On the other hand, development of the other two bexmarilimab trials MATINS (bex monotherapy in solid tumors) and BEXCOMBO (bex combined with PD-1 inhibitors) have been a bit slower than we anticipated probably due to lack of funding. We commneted on biotech funding recently here.
We will be updating our extensive report by the end of the year and provide regular updates on the stock in the mean time. The latest one is Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation